134 related articles for article (PubMed ID: 24440965)
1. Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results.
Claret L; Bruno R; Lu JF; Sun YN; Hsu CP
Clin Pharmacol Ther; 2014 Apr; 95(4):446-51. PubMed ID: 24440965
[TBL] [Abstract][Full Text] [Related]
2. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.
Kubota K; Ichinose Y; Scagliotti G; Spigel D; Kim JH; Shinkai T; Takeda K; Kim SW; Hsia TC; Li RK; Tiangco BJ; Yau S; Lim WT; Yao B; Hei YJ; Park K
Ann Oncol; 2014 Feb; 25(2):529-36. PubMed ID: 24419239
[TBL] [Abstract][Full Text] [Related]
3. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Kubota K; Yoshioka H; Oshita F; Hida T; Yoh K; Hayashi H; Kato T; Kaneda H; Yamada K; Tanaka H; Ichinose Y; Park K; Cho EK; Lee KH; Lin CB; Yang JC; Hara K; Asato T; Nakagawa K
J Clin Oncol; 2017 Nov; 35(32):3662-3670. PubMed ID: 28902534
[TBL] [Abstract][Full Text] [Related]
4. Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
Bass MB; Yao B; Hei YJ; Ye Y; Davis GJ; Davis MT; Kaesdorf BA; Chan SS; Patterson SD
PLoS One; 2014; 9(10):e108048. PubMed ID: 25314641
[TBL] [Abstract][Full Text] [Related]
5. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
[TBL] [Abstract][Full Text] [Related]
6. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Novello S; Scagliotti GV; Sydorenko O; Vynnychenko I; Volovat C; Schneider CP; Blackhall F; McCoy S; Hei YJ; Spigel DR
J Thorac Oncol; 2014 Aug; 9(8):1154-61. PubMed ID: 25157768
[TBL] [Abstract][Full Text] [Related]
7. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.
Claret L; Lu JF; Bruno R; Hsu CP; Hei YJ; Sun YN
Clin Pharmacol Ther; 2012 Nov; 92(5):631-4. PubMed ID: 22910440
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
[TBL] [Abstract][Full Text] [Related]
9. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
[TBL] [Abstract][Full Text] [Related]
10. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
Blumenschein GR; Reckamp K; Stephenson GJ; O'Rourke T; Gladish G; McGreivy J; Sun YN; Ye Y; Parson M; Sandler A
Clin Cancer Res; 2010 Jan; 16(1):279-90. PubMed ID: 20028752
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
Coxon A; Ziegler B; Kaufman S; Xu M; Wang H; Weishuhn D; Schmidt J; Sweet H; Starnes C; Saffran D; Polverino A
Mol Cancer; 2012 Sep; 11():70. PubMed ID: 22992329
[TBL] [Abstract][Full Text] [Related]
12. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
Chiappori AA; Kolevska T; Spigel DR; Hager S; Rarick M; Gadgeel S; Blais N; Von Pawel J; Hart L; Reck M; Bassett E; Burington B; Schiller JH
Ann Oncol; 2015 Feb; 26(2):354-62. PubMed ID: 25467017
[TBL] [Abstract][Full Text] [Related]
14. Motesanib and advanced NSCLC: experiences and expectations.
Raghav KP; Blumenschein GR
Expert Opin Investig Drugs; 2011 Jun; 20(6):859-69. PubMed ID: 21534718
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis Inhibitors in NSCLC.
Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
De Boer RH; Kotasek D; White S; Koczwara B; Mainwaring P; Chan A; Melara R; Ye Y; Adewoye AH; Sikorski R; Kaufman PA
Breast Cancer Res Treat; 2012 Aug; 135(1):241-52. PubMed ID: 22872523
[TBL] [Abstract][Full Text] [Related]
17. Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study).
Morgensztern D; Herbst RS
J Clin Oncol; 2012 Aug; 30(23):2805-8. PubMed ID: 22753916
[No Abstract] [Full Text] [Related]
18. Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Lu S; Cheng Y; Zhou CC; Wang J; Chih-Hsin Yang J; Zhang PH; Zhang XQ; Wang X; Orlando M; Wu YL
Clin Lung Cancer; 2016 Sep; 17(5):e103-e112. PubMed ID: 27236385
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis for the efficacy of S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer.
Chen J; Wang J; Wu X; Che X; Zou Y; Weng M; Miao Q; Zheng Q
Future Oncol; 2017 Oct; 13(24):2195-2207. PubMed ID: 28994614
[TBL] [Abstract][Full Text] [Related]
20. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
